Genedrive PLC Block listing Interim Review (2920V)
01 December 2023 - 4:29AM
UK Regulatory
TIDMGDR
RNS Number : 2920V
Genedrive PLC
30 November 2023
genedrive plc
("genedrive" or the "Company")
Block Listing Returns
The Company confirms the block listing six monthly return for
the period to 30 November 2023.
Name of applicant genedrive plc
Name of scheme 2007 Share Option Scheme
--------------------------------------------
Period of return: From: 01 June 2023 To: 30 November 2023
------------------ ------------- ---- -----------------------
Balance of unallocated securities 131,726 shares
under scheme(s) from previous
return:
--------------------------------------------
Plus: The amount by which the Nil
block scheme(s) has been increased
since the date of the last return
(if any increase has been applied
for):
--------------------------------------------
Less: Number of securities issued/allotted Nil
under scheme(s) during period
(see LR3.5.7G):
--------------------------------------------
Equals: Balance under scheme(s) 131,726 shares
not yet issued/allotted at end
of period:
--------------------------------------------
Name of applicant genedrive plc
Name of scheme 2017 Share Option Scheme
--------------------------------------------
Period of return: From: 01 June 2023 To: 30 November 2023
------------------ ------------- ---- -----------------------
Balance of unallocated securities 1,150,588 shares
under scheme(s) from previous
return:
--------------------------------------------
Plus: The amount by which the Nil
block scheme(s) has been increased
since the date of the last return
(if any increase has been applied
for):
--------------------------------------------
Less: Number of securities issued/allotted Nil
under scheme(s) during period
(see LR3.5.7G):
--------------------------------------------
Equals: Balance under scheme(s) 1,150,588 shares
not yet issued/allotted at end
of period:
--------------------------------------------
Name of applicant genedrive plc
Name of scheme Unapproved Share Option Scheme
--------------------------------------------
Period of return: From: 01 June 2023 To: 30 November 2023
------------------- ------------- ---- -----------------------
Balance of unallocated securities 2,668,144 shares
under scheme(s) from previous
return:
--------------------------------------------
Plus: The amount by which the Nil
block scheme(s) has been increased
since the date of the last return
(if any increase has been applied
for):
--------------------------------------------
Less: Number of securities issued/allotted Nil
under scheme(s) during period
(see LR3.5.7G):
--------------------------------------------
Equals: Balance under scheme(s) 2,668,144 shares
not yet issued/allotted at end
of period:
--------------------------------------------
Name of contact: Russ Shaw CFO
--------------------------------------------
Telephone number of contact: +44 (0)161 989 0245
--------------------------------------------
For enquires:
genedrive plc +44 (0)161 989 0245
James Cheek: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
Anna Dunphy +44 (0)7876 741 001
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a pharmacogenetic testing company developing
and commercialising a low cost, rapid, versatile, simple to use and
robust point of need pharmacogenetic platform for the diagnosis of
genetic variations. This helps clinicians to quickly access key
genetic information that will help them make the right choices over
the right medicine or dosage to use for an effective treatment.
Based in the UK, the Company is at the forefront of work on Point
of Care pharmacogenetics. Pharmacogenetics looks at how your
genetics impacts a medicines ability to work for you. Therefore by
using pharmacogenetics, medicines can be made safer and more
effective. The Company has launched its flagship product, the
Genedrive(R) MT-RNR1 ID Kit, which is a single-use disposable
cartridge which circumvents the requirement for cold chain
logistics by providing temperature stable reagent test kits for use
on their proprietary test platform. This test allows clinicians to
make a decision on antibiotic use within 26 minutes, ensuring vital
care is delivered with no negative impact on the patient
pathway.
The Company has a clear commercial strategy focused on
accelerating growth through maximising in-market sales, geographic
and portfolio expansion and strategic M&A, and operates out of
its facilities in Manchester.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRURUBROWUAOAA
(END) Dow Jones Newswires
November 30, 2023 12:29 ET (17:29 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024
